ReviewDaru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences2026
Beyond Nanosizing: Mechanism-Guided Design and Rational Selection of Polymeric and Lipid Nanocarriers for Translatable Drug Delivery.
Review in Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNanosizing can modify dissolution and carrier behaviour, but particle size alone does not determine clinically useful exposure.
objectiveTo compare polymeric and lipid-based nanocarriers using a mechanism-guided framework that links payload properties, composition, process conditions, biological barriers, critical quality attributes (CQAs), and translational risk.
methodsA critical narrative review with a structured scoping update was performed using PubMed, Scopus, Web of Science, and Google Scholar during manuscript preparation. The intended publication window was 2010-2025, with earlier seminal studies retained where mechanistically necessary. Because exact search dates, an auditable database export, screening counts, and independent-reviewer records were not preserved, this review is not presented as a systematic review and no pooled effect estimate is reported.
resultsPolymeric systems can stabilize selected amorphous or molecularly dispersed payloads and tune release through diffusion, hydration, and degradation, whereas lipid systems can support lipid-phase solubilization, digestion-dependent oral absorption, membrane interaction, and nucleic-acid delivery. Across both classes, precipitation, release failure, phase transformation, protein-corona and immune effects, endosomal sequestration, and process drift can disconnect favorable in vitro attributes from human pharmacology. Clinical examples show product-specific changes in disposition, safety, or efficacy rather than a universal bioavailability multiplier.
conclusionRational nanocarrier selection should start from a testable mechanism and a defined translational risk, then be challenged with route-relevant biological assays, exposure measurements, safety data, and manufacturing comparability. The proposed framework is hypothesis-generating and requires prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.